D&D Pharmatech Co., Ltd.

As of June 30, 2026, D&D Pharmatech Co., Ltd. carries a market capitalization of 3.83T, placing it among publicly traded companies globally. Its enterprise value stands at 3.80T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, D&D Pharmatech Co., Ltd. has 43.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,389.57, and the price-to-book ratio stands at 28.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,379.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.80T versus a market cap of 3.83T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, D&D Pharmatech Co., Ltd. maintains a current ratio of 27.21, meaning it holds 27.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 85.83, indicating elevated leverage, while an interest coverage ratio of -10.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, D&D Pharmatech Co., Ltd. posted a negative return on equity (ROE) of -20.24, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.33, reflecting losses generated across the asset base. The company generates approximately 122.24M in revenue per employee across its workforce of 22.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, D&D Pharmatech Co., Ltd. recorded an income tax benefit of -939.73M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -22.69B and -21.60B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, D&D Pharmatech Co., Ltd.'s stock has declined approximately 3.95% over the past 52 weeks. The 50-day moving average sits at 48,515.00, while the 200-day moving average is 72,790.00.

Over the twelve months ended June 30, 2026, D&D Pharmatech Co., Ltd. generated 2.75B in revenue and converted that into -21.60B in net income, yielding earnings per share of -541.15. EBITDA reached -31.96B, while operating income came in at -37.62B.

As of June 30, 2026, D&D Pharmatech Co., Ltd. holds 152.26B in cash and equivalents against 115.09B in total debt, resulting in a net debt position of 97.30B. Total book value stands at 134.73B, with working capital of 178.36B providing operational flexibility.

D&D Pharmatech Co., Ltd. produced -24.89B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -37.07M in capital expenditures, free cash flow totaled -24.93B - equivalent to -570.79 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,367.89 and net profit margin of -785.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.94, meaning D&D Pharmatech Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

D&D Pharmatech Co., Ltd.'s most recent stock split took place on November 13, 2025 with a 1:4 split ratio.

As of June 30, 2026, D&D Pharmatech Co., Ltd. has an Altman Z-Score of 11.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.